Canaglif lozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: A randomized, double-blind, phase 3 study

Diabetes Care

Volumn 38, Issue 3, 2015, Pages 355-364

  Leiter, Lawrence A ^a   Yoon, Kun Ho ^b   Arias, Pablo ^c,d   Langslet, Gisle ^e   Xie, John ^f   Balis, Dainius A ^f   Millington, Dawn ^f   Vercruysse, Frank ^g   Canovatchel, William ^f   Meininger, Gary ^f  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b The Catholic University of Korea   (South Korea)

^c UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

^d Litoral University Medical School   (Argentina)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^g JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; GLIMEPIRIDE; HEMOGLOBIN A1C; METFORMIN; BLOOD GLUCOSE; GLUCOSIDES; HYPOGLYCEMIC AGENTS; SULFONYLUREA COMPOUNDS; THIOPHENES;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETES CONTROL; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FUNGAL GENITAL INFECTION; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MICTURITION DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OSMOTIC DIURESIS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; URINARY TRACT INFECTION; WEIGHT REDUCTION; BLOOD; BLOOD GLUCOSE; BODY WEIGHT; CHEMICALLY INDUCED; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG EFFECTS; DRUG THERAPY, COMBINATION; HUMANS; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; TIME FACTORS; TREATMENT OUTCOME; WEIGHT LOSS;

BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSIDES; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; SULFONYLUREA COMPOUNDS; THIOPHENES; TIME FACTORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84940110139     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-2762     Document Type: Article

References (36)

1. Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitusd present and future perspectives. Nat Rev Endocrinol 2011;8:228-236.
2. Inzucchi SE, Bergenstal RM, Buse JB, et al.; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-1379.
3. Bays HE, Gonźalez-Campoy JM, Bray GA, et al. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther 2008;6:343-368.
4. Wing RR, Lang W, Wadden TA, et al.; Look AHEAD Research Group. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 2011;34:1481- 1486.
5. Cook MN, Girman CJ, Stein PP, Alexander CM. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care. Diabet Med 2007;24:350-358.
6. Brown JB, Conner C, Nichols GA. Secondary failure of metformin monotherapy in clinical practice. Diabetes Care 2010;33:501-506.
7. Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: An update including new drugs and 2-drug combinations. Ann Intern Med 2011;154:602-613.
8. Neumiller JJ, White JR Jr, Campbell RK. Sodium-glucose co-transport inhibitors: Progress and therapeutic potential in type 2 diabetes mellitus. Drugs 2010;70:377-385.
9. Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 2011;32:515-531.
10. Chao EC, Henry RR. SGLT2 inhibitionda novel strategy for diabetes treatment. Nat Rev Drug Discov 2010;9:551-559.
11. Bode B, Stenlof K, Sullivan D, Fung A, Usiskin K. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: A randomized trial. Hosp Pract (1995) 2013;41: 72-84.
12. Cefalu WT, Leiter LA, Yoon K-H, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013;382:941-950.
13. Rosenstock J, Aggarwal N, Polidori D, et al.; Canagliflozin DIA 2001 Study Group. Dose-rangingeffects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012;35:1232-1238.
14. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: A 52-week randomized trial. Diabetes Care 2013;36:2508-2515.
15. Stenlof K, Cefalu WT, Kim K-A, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013;15:372-382.
16. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013;15:463-473.
17. Lavalle-Gonźalez FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: A randomised trial. Diabetologia 2013;56:2582-2592.
18. Wilding JP, Charpentier G, Hollander P, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: A randomised trial. Int J Clin Pract 2013;67:1267-1282.
19. Kahn SE, Haffner SM, Heise MA, et al.; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-2443.
20. Gallwitz B, Rosenstock J, Rauch T, et al. 2- year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: A randomised, double-blind, non-inferiority trial. Lancet 2012;380:475-483.
21. Matthews DR, Dejager S, Ahren B, et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: Results from a 2-year study. Diabetes Obes Metab 2010;12:780-789.
22. Nauck M, Frid A, Hermansen K, et al.; LEAD- 2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009;32:84-90.
23. Jendle J, Nauck MA, Matthews DR, et al.; LEAD-2 and LEAD-3 Study Groups. Weight loss with liraglutide, a once-daily human glucagonlike peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab 2009;11:1163- 1172.
24. Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012;97:1020- 1031.
25. Blonde L, Wilding J, Chiasson J-L, Polidori D, Meininger G, Stein P. Canagliflozin (CANA) lowers A1C and blood pressure (BP) through weight loss-independent (WL-I) andweight loss-associated (WL-A) mechanisms (Abstract). Diabetes 2013; 62:A288.
26. FARXIGA (dapagliflozin) [package insert]. Princeton, NJ, Bristol-Myers Squibb Company, 2014.
27. INVOKANA (canagliflozin) [package insert]. Titusville, NJ, Janssen Pharmaceuticals, 2013.
28. Neal B, Perkovic V, deZeeuw D, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)da randomized placebo-controlled trial. Am Heart J 2013;166:217-223, e11.
29. Bristol-Myers Squibb/AstraZeneca EEIG. Forxiga 5 mg and 10 mg film-coated tablets: summary of product characteristics [Internet], 2012. Middlesex, U.K., Bristol-Myers Squibb/AstraZeneca EEIG. Available from http://www.medicines.org.uk/emc/history/27188/SPC/Forxiga+5+mg++%26+10+mg+film+coated+tablets. Accessed 16 July 2014.
30. Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications 2013;27:479-484.
31. Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications 2013;27:473-478.
32. Rosenstock J, Seman LJ, Jelaska A, et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab 2013;15:1154-1160.
33. Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 2012;14:539-545.
34. Nauck M, Del Prato S, Rohwedder K, Theuerkauf A, Langkilde AM, Parikh SJ. Longterm efficacy and safety of add-on dapagliflozin vs add-on glipizide in patients with T2DM inadequately controlled with metformin: 2-year results (Abstract). Diabetes 2011;60:LB12.
35. Williams-Herman D, Round E, Swern AS, et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: A pooled analysis. BMC Endocr Disord 2008;8:14.
36. Janssen Research & Development LLC. Canagliflozin as an adjunctive treatment to diet and exercise alone or co-administered with other antihyperglycemic agents to improve glycemic control in adults with type 2 diabetes mellitus. JNJ-28431754 (Canagliflozin), NDA 204042 [Internet], 2013. Silver Spring, MD, Endocrinologic and Metabolic Drugs Advisory Committee, U.S. Food and Drug Administration. Available from http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM334551.pdf. Accessed 16 July 2014.